The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies

被引：2

作者：

Rabenstein, Monika ^{[1
,2
,3
,4
]}

Thomas, Olivia G. ^{[1
,2
]}

Carlin, Giorgia ^{[2
]}

Khademi, Mohsen ^{[1
]}

Hogelin, Klara Asplund ^{[1
]}

Malmestrom, Clas ^{[5
]}

Axelsson, Markus ^{[5
]}

Brandt, Anne Frandsen ^{[5
]}

Gafvelin, Guro ^{[2
]}

Gronlund, Hans ^{[2
]}

Kockum, Ingrid ^{[1
]}

Piehl, Fredrik ^{[1
]}

Lycke, Jan ^{[5
]}

Olsson, Tomas ^{[1
,7
]}

Hessa, Tara ^{[1
,2
,6
]}

机构：

[1] Karolinska Inst, Ctr Mol Med L802, Dept Clin Neurosci, Therapeut Immune Design, Stockholm, Sweden

[2] Karolinska Inst, Ctr Mol Med L804, Dept Clin Neurosci, Neuroimmunol Unit, Stockholm, Sweden

[3] Univ Cologne, Fac Med, Dept Neurol, Cologne, Germany

[4] Univ Cologne, Univ Hosp, Cologne, Germany

[5] Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Dept Clin Neurosci, Gothenburg, Sweden

[6] Karolinska Inst, Ctr Mol Med L802, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden

[7] Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷 / 12期

基金：

瑞典研究理事会;

关键词：

cellular immunity; humoral immunity; multiple sclerosis; SARS-CoV-2; vaccination;

D O I：

10.1111/ene.16015

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background and purpose: Hybrid immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develops from a combination of natural infection and vaccine-generated immunity. Multiple sclerosis (MS) disease-modifying therapies (DMTs) have the potential to impact humoral and cellular immunity induced by SARS-CoV-2 vaccination and infection. The aims were to compare antibody and T-cell responses after SARS-CoV-2 mRNA vaccination in persons with MS (pwMS) treated with different DMTs and to assess differences between naively vaccinated pwMS and pwMS with hybrid immunity vaccinated following a previous SARS-CoV-2 infection.Methods: Antibody and T-cell responses were determined in pwMS at baseline and 4 and 12 weeks after the second dose of SARS-CoV-2 vaccination in 143 pwMS with or without previous SARS-CoV-2 infection and 40 healthy controls (HCs). The MS cohort comprised natalizumab (n = 22), dimethylfumarate (n = 23), fingolimod (n = 38), cladribine (n = 30), alemtuzumab (n = 17) and teriflunomide (n = 13) treated pwMS. Immunoglobulin G antibody responses to SARS-CoV-2 antigens were measured using a multiplex bead assay and FluoroSpot was used to assess T-cell responses (interferon gamma and interleukin 13).Results: Humoral and T-cell responses to vaccination were comparable between naively vaccinated HCs and pwMS treated with natalizumab, dimethylfumarate, cladribine, alemtuzumab and teriflunomide, but were suppressed in fingolimod-treated pwMS. Both fingolimod-treated pwMS and HCs vaccinated following a previous SARS-CoV-2 infection had higher antibody levels 4 weeks after vaccination compared to naively vaccinated individuals. Antibody and interferon gamma levels 12 weeks after vaccination were positively correlated with time from last treatment course of cladribine.Conclusion: These findings are of relevance for infection risk mitigation and for vaccination strategies amongst pwMS undergoing DMT.

引用

页码：3789 / 3798

页数：10

共 45 条

[1] Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod [J].

Achiron, Anat ;

Mandel, Mathilda ;

Gurevich, Michael ;

Dreyer-Alster, Sapir ;

Magalashvili, David ;

Sonis, Polina ;

Dolev, Mark ;

Menascu, Shay ;

Harari, Gil ;

Flechter, Shlomo ;

Falb, Rina .

JOURNAL OF NEUROLOGY, 2022, 269 (05) :2286-2292

[2] Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies [J].

Achiron, Anat ;

Mandel, Mathilda ;

Dreyer-Alster, Sapir ;

Harari, Gil ;

Magalashvili, David ;

Sonis, Polina ;

Dolev, Mark ;

Menascu, Shay ;

Flechter, Shlomo ;

Falb, Rina ;

Gurevich, Michael .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14

[3] SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot [J].

Achtnichts, Lutz ;

Ovchinnikov, Arkady ;

Jakopp, Barbara ;

Oberle, Michael ;

Nedeltchev, Krassen ;

Fux, Christoph Andreas ;

Sellner, Johann ;

Findling, Oliver .

VACCINES, 2022, 10 (02)

[4] Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies [J].

Aiello, Alessandra ;

Coppola, Andrea ;

Ruggieri, Serena ;

Farroni, Chiara ;

Altera, Anna Maria Gerarda ;

Salmi, Andrea ;

Vanini, Valentina ;

Cuzzi, Gilda ;

Petrone, Linda ;

Meschi, Silvia ;

Lapa, Daniele ;

Bettini, Aurora ;

Haggiag, Shalom ;

Prosperini, Luca ;

Galgani, Simonetta ;

Quartuccio, Maria Esmeralda ;

Bevilacqua, Nazario ;

Garbuglia, Anna Rosa ;

Agrati, Chiara ;

Puro, Vincenzo ;

Tortorella, Carla ;

Gasperini, Claudio ;

Nicastri, Emanuele ;

Goletti, Delia .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2023, 94 (04) :290-299

[5] Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy [J].

Apostolidis, Sokratis A. ;

Kakara, Mihir ;

Painter, Mark M. ;

Goel, Rishi R. ;

Mathew, Divij ;

Lenzi, Kerry ;

Rezk, Ayman ;

Patterson, Kristina R. ;

Espinoza, Diego A. ;

Kadri, Jessy C. ;

Markowitz, Daniel M. ;

Markowitz, Clyde E. ;

Mexhitaj, Ina ;

Jacobs, Dina ;

Babb, Allison ;

Betts, Michael R. ;

Prak, Eline T. Luning ;

Weiskopf, Daniela ;

Grifoni, Alba ;

Lundgreen, Kendall A. ;

Gouma, Sigrid ;

Sette, Alessandro ;

Bates, Paul ;

Hensley, Scott E. ;

Greenplate, Allison R. ;

Wherry, E. John ;

Li, Rui ;

Bar-Or, Amit .

NATURE MEDICINE, 2021, 27 (11) :1990-+

[6] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].

Baden, Lindsey R. ;

El Sahly, Hana M. ;

Essink, Brandon ;

Kotloff, Karen ;

Frey, Sharon ;

Novak, Rick ;

Diemert, David ;

Spector, Stephen A. ;

Rouphael, Nadine ;

Creech, C. Buddy ;

McGettigan, John ;

Khetan, Shishir ;

Segall, Nathan ;

Solis, Joel ;

Brosz, Adam ;

Fierro, Carlos ;

Schwartz, Howard ;

Neuzil, Kathleen ;

Corey, Larry ;

Gilbert, Peter ;

Janes, Holly ;

Follmann, Dean ;

Marovich, Mary ;

Mascola, John ;

Polakowski, Laura ;

Ledgerwood, Julie ;

Graham, Barney S. ;

Bennett, Hamilton ;

Pajon, Rolando ;

Knightly, Conor ;

Leav, Brett ;

Deng, Weiping ;

Zhou, Honghong ;

Han, Shu ;

Ivarsson, Melanie ;

Miller, Jacqueline ;

Zaks, Tal .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416

[7] The differential expression of IL-4 and IL-13 and its impact on type-2 immunity [J].

Bao, Katherine ;

Reinhardt, R. Lee .

CYTOKINE, 2015, 75 (01) :25-37

[8] Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments [J].

Bock, H. ;

Juretzek, T. ;

Handreka, R. ;

Ruhnau, J. ;

Lobel, M. ;

Reuner, K. ;

Peltroche, H. ;

Dressel, A. .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59

[9] Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab [J].

Brill, Livnat ;

Rechtman, Ariel ;

Zveik, Omri ;

Haham, Nitzan ;

Oiknine-Djian, Esther ;

Wolf, Dana G. ;

Levin, Netta ;

Raposo, Catarina ;

Vaknin-Dembinsky, Adi .

JAMA NEUROLOGY, 2021, 78 (12) :1510-1514

[10] Effects of MS disease-modifying therapies on responses to vaccinations: A review [J].

Ciotti, John Robert ;

Valtcheva, Manouela V. ;

Cross, Anne Haney .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 45

← 1 2 3 4 5 →